DGKD and nephrolithiasis: These results may have direct clinical utility in facilitating the prediction of kidney stone recurrence risk and thereby motivate lifestyle modifications and the selection of therapeutic interventions such as calcimimetics to ameliorate DGKδ-mediated CaSR signaling perturbations; phosphate supplements to increase serum phosphate in NaPi-IIa–associated KSD; or inhibitors of vitamin D activation (for example triazole drugs or rifampicin) and/or avoidance of vitamin D supplementation, in which 24-hydroxylase–mediated 1,25-dihydroxyvitamin D inactivation is likely impaired.